![Benjamin John Nathan Griffiths](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Career history of Benjamin John Nathan Griffiths
Former positions of Benjamin John Nathan Griffiths
Companies | Position | Start | End |
---|---|---|---|
Abcellute Ltd.
![]() Abcellute Ltd. Miscellaneous Commercial ServicesCommercial Services Abcellute was founded in September 2001 as a spinout from the school of biosciences, Cardiff University. Abcellute's core technology is proprietary media Sure Tran -that enables the extended use of fresh cells with out the need for cryopreservation. The company's vision is to achieve global adoption of its SureTran cell transport technology by providing the research community with enhanced, fresh-cell systems. These will maximize the utilization of this often scarce resource and provide products that are much more convenient to use than current fresh-cell systems. This will deliver benefits to biomedical researchers in key areas such as pre-clinical drug evaluation and regenerative medicine. | Chief Tech/Sci/R&D Officer | 01/09/2001 | 20/11/2012 |
Founder | 19/04/2010 | 20/11/2012 |
Statistics
International
United Kingdom | 2 |
Operational
Chief Tech/Sci/R&D Officer | 1 |
Founder | 1 |
Sectoral
Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 1 |
---|---|
Abcellute Ltd.
![]() Abcellute Ltd. Miscellaneous Commercial ServicesCommercial Services Abcellute was founded in September 2001 as a spinout from the school of biosciences, Cardiff University. Abcellute's core technology is proprietary media Sure Tran -that enables the extended use of fresh cells with out the need for cryopreservation. The company's vision is to achieve global adoption of its SureTran cell transport technology by providing the research community with enhanced, fresh-cell systems. These will maximize the utilization of this often scarce resource and provide products that are much more convenient to use than current fresh-cell systems. This will deliver benefits to biomedical researchers in key areas such as pre-clinical drug evaluation and regenerative medicine. | Commercial Services |